Stocks News

LAST PRICE
44.0200
TODAY'S CHANGE (%)
Trending Down-0.2200 (-0.4973%)

Bid / Lots
38.5000/ 3
Ask / Lots
45.5300/ 1
Open / Previous Close
44.5200 / 44.2400
Day Range
Low 43.9200
High 45.3600
52 Week Range
Low 31.5200
High 54.9800
Volume
625,791
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 25, 2024
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update, from 4:30PM ET on Thursday Apr 25, 2024 by Dow Jones
  4:30PM ET on Thursday Apr 25, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
  
  NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
Apr 24, 2024
- DJ Ultragenyx Pharma Is Maintained at Buy by TD Cowen, from 1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones
  1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RARE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 24, 2024 13:33 ET (17:33 GMT)
Apr 22, 2024
- --RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward, from 6:56AM ET on Monday Apr 22, 2024 by MT Newswires
  6:56AM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: RARE
  06:56 AM EDT, 04/22/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
- DJ Ultragenyx Pharma Initiated at Outperform by RBC Capital, from 5:51AM ET on Monday Apr 22, 2024 by Dow Jones
  5:51AM ET on Monday Apr 22, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RARE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 22, 2024 05:51 ET (09:51 GMT)
Apr 19, 2024
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Apr 19, 2024 by Dow Jones
  4:30PM ET on Friday Apr 19, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  
  NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company's common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Today
- Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: AXSM
- Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90, from 13 hours ago by MT Newswires
  13 hours ago by MT Newswires
  Companies Mentioned: AXSM
Apr 25, 2024
- Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024, from 8:01AM ET on Thursday Apr 25, 2024 by PR Newswire
  8:01AM ET on Thursday Apr 25, 2024 by PR Newswire
  Companies Mentioned: INSM
Apr 23, 2024
- --Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases, from 6:12AM ET on Tuesday Apr 23, 2024 by MT Newswires
  6:12AM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: INSM
Apr 22, 2024
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, from 4:30PM ET on Monday Apr 22, 2024 by GlobeNewswire
  4:30PM ET on Monday Apr 22, 2024 by GlobeNewswire
  Companies Mentioned: CRSP
Apr 18, 2024
- --Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating, from 12:32PM ET on Thursday Apr 18, 2024 by MT Newswires
  12:32PM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: CRSP
Apr 17, 2024
- AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Wednesday Apr 17, 2024 by GlobeNewswire
  9:00PM ET on Wednesday Apr 17, 2024 by GlobeNewswire
  Companies Mentioned: AXSM
- Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing, from 5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires
  5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: CRSP
Apr 15, 2024
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting, from 7:00AM ET on Monday Apr 15, 2024 by GlobeNewswire
  7:00AM ET on Monday Apr 15, 2024 by GlobeNewswire
  Companies Mentioned: AXSM
Apr 12, 2024
- AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 2:30AM ET on Friday Apr 12, 2024 by GlobeNewswire
  2:30AM ET on Friday Apr 12, 2024 by GlobeNewswire
  Companies Mentioned: AXSM

Ultragenyx Pharmaceutical Inc
NASDAQ:RAREUnited States

Search Criteria

Apr 25, 2024

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update, from 4:30PM ET on Thursday Apr 25, 2024 by Dow Jones

Apr 24, 2024

DJ Ultragenyx Pharma Is Maintained at Buy by TD Cowen, from 1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones

Apr 22, 2024

--RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward, from 6:56AM ET on Monday Apr 22, 2024 by MT Newswires

DJ Ultragenyx Pharma Initiated at Outperform by RBC Capital, from 5:51AM ET on Monday Apr 22, 2024 by Dow Jones

Apr 19, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Apr 19, 2024 by Dow Jones

Peers Headlines

Today

Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says, from 6 hours ago by MT Newswires

Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90, from 13 hours ago by MT Newswires

Apr 25, 2024

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024, from 8:01AM ET on Thursday Apr 25, 2024 by PR Newswire

Apr 23, 2024

--Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases, from 6:12AM ET on Tuesday Apr 23, 2024 by MT Newswires

Apr 22, 2024

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, from 4:30PM ET on Monday Apr 22, 2024 by GlobeNewswire

Apr 18, 2024

--Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating, from 12:32PM ET on Thursday Apr 18, 2024 by MT Newswires

Apr 17, 2024

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Wednesday Apr 17, 2024 by GlobeNewswire

Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing, from 5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires

Apr 15, 2024

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting, from 7:00AM ET on Monday Apr 15, 2024 by GlobeNewswire

Apr 12, 2024

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 2:30AM ET on Friday Apr 12, 2024 by GlobeNewswire